NY-ESO-1 immunotherapy combination demonstrates preclinical efficacy in glioblastoma

Written by Emily Brown, Future Science Group

A team of investigators based at the University of California, Los Angeles (UCLA; CA, USA), has proposed a potential new drug combination that could be effective against glioblastoma. Published yesterday in Neuro-Oncology, the findings suggest that decitabine in combination with modified T-cell immunotherapy was effective at curing almost 50% of glioblastomas in a mouse model. Following on from work published in 2011, the team led by Robert Prins and Linda Liau (both of UCLA’s Jonsson Comprehensive Cancer Center) investigated an adoptive cell transfer treatment method in a preclinical animal model. Growing T cells were isolated and reprogrammed with a gene...

To view this content, please register now for access

It's completely free